A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily

British Journal of Cancer

Volumn 74, Issue 9, 1996, Pages 1482-1486

  Savage, P ^a   Horton, V ^b   Moore, J ^a   Owens, M ^b   Witt, P ^c   Gore, M E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b 3M COMPANY   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Imiquimod; Immunotherapy; Interferon

Indexed keywords

BETA 2 MICROGLOBULIN; IMIQUIMOD; INTERFERON; INTERFERON INDUCING AGENT; INTERLEUKIN 1; NEOPTERIN; SYNTHETASE; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOSOL; FEMALE; HUMAN; HUMAN CELL; INFLUENZA; INTERFERON PRODUCTION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; MONONUCLEAR CELL; NAUSEA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; REFRACTORY PERIOD; VOMITING;

EID: 0029824158     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.569     Document Type: Article

References (22)

1. CREEKMORE SP, URBA WJ AND LONGO DL. (1991). Principles of the clinical evaluation of biologic agents. In Biological therapy of cancer. Devita VT, Hellman S and Rosenberg SA. (eds). pp. 67-86. JB Lippincott Co: Philadelphia.
2. DIANZANI F. (1992). Interferon treatments: how to use an endogenous system as a therapeutic agent. J. Interferon Res., 12, 109-118.
3. GROSSBERG SE, TAYLOR JL, SIEBENLIST RE AND JAMSON P. (1986). Biological and immunological assays of human interferons. In Manual of Clinical Laboratory Immunology. Rose NR, Friedman H and Fahey JL (eds), 3rd ed. pp. 295-299. American Society for Microbiology: Washinton DC.
4. HOROSZEWICZ JS AND MURPHY GP. (1989). An assessment of the current use of human interferons in the therapy of urological cancers. J. Urol., 142, 1173-1180.
5. HOVANESSIAN AG, YOUN YK, BUFFET-JANVRESSE C, RIVIERE Y, MICHELSON M, LACOUR J AND LACOUR F. (1985). Enhancement of natural killer cell activity and 2-5 adenylate synthetase in operable breast cancer patients treated with polyadenylic:polyuridylic acid. Cancer, 55, 357-362.
6. MAYER GD AND KRUEGER RF. (1970). Tilorone hydrochloride: mode of action. Science, 169, 1214-1215.
7. MILLER AB, HOOGSTRATEN B, STAQUET M AND WINKLER A. (1981). Reporting results of cancer treatment. Cancer. 47, 207-214.
8. NICHOL FR, WEED SD AND UNDERWOOD GE. (1976). Stimulation of murine interferon by a substituted pyrimidine. Antimicrob. Agents Chemother., 9, 433-439.
9. QUESADA JR, REUBEN J, MANNING JT, HERSH EM AND GUTTERMAN JU. (1984). Alpha interferon for induction of remission in hairy-cell leukemia. N. Engl. J. Med., 310, 15-18.
10. REITER MJ, TESTERMAN TL, MILLER RL, WEEKS CE AND TOMAI MA. (1994). Cytokine induction in mice by the immunomodulator imiquimod. J. Leukocyte biol., 55, 234-240.
11. RIOS A, STRINGFELLOW DA, FITZPATRICK FA, REELE SB, GUTKNECHT GD AND HERSH EM. (1986). Phase I study of 2-atnino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP), an oral interferon inducer, in cancer patients. J. biol. Response Modifiers, 5, 330-338.
12. SAROSDY MF, LAMM DL, WILLIAMS RD, MOON TD, FLANIGAN RC, CRAWFORD ED, WILKS NE, EARHART RH AND MERRITT JA. (1992). Phase I trial of oral bropirimine in superficial bladder cancer. J. Urol., 147, 31-33.
13. SIDKY YA, BRYAN GT, WEEKS CE, HATCHER JM AND BORDEN EC. (1990). Effects of treatment with an oral interferon inducer, imidazoquinolinamine (R837), on the growth of mouse bladder carcinoma FCB. J. Interferon Res., 10, (suppl. 1), S123.
14. SIDKY YA, BORDEN EC, WEEKS CE, REITER MJ, HATCHER JF AND BRYAN GT. (1992u). Inhibition of murine tumor growth by an interferon inducing imidazoquinoline. Cancer Res., 52, 3528-3533.
15. SIDKY YA, BORDEN EC AND WEEKS CE. (1992b). Inhibition of tumor-induced angiogenesis by the interferon inducer imiquimod. Proc. Am. Ass. Cancer Res., 33, 458.
16. STEISS RG, SMITH JW, URBA WJ, CLARK JW, ITRI LM, EVANS LM, SCHOENBERGER C AND LONGO DL. (1988). Resistance to recombinant interferon alpha 2a in hairy cell leukaemia associated with neutralising anti-interferon antibodies. N. Engl. J. Med., 318, 1409 1413.
17. STRINGFELLOW DA, WEED SD AND UNDERWOOD GE. (1979). Antiviral and interferon inducing properties of 1,5 diaminoanthraquinones. Antimicrob. Agents Chemother., 15, 111 118.
18. VON WUSSOW P, BLOCK B, HARTMANN F AND DEICHER H. (1988). Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer. 61, 1071-1074.
19. WEEKS CE AND GIBSON SJ. (1994). Induction of interferon and other cytokines by imiquimod and it's hydroxylated metabolite R-842 in human blood cells in vitro. J. Interferon Res., 14, 81-85.
20. WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION. (1983). Standardization of Interferons. WHO Technical Report Series No. 687. WHO: Geneva.
21. WICK KA, KVAM DC, WEEKS CE, DIXON RM, HAFSTAD K AND WITT PL. (1991). Oral R-837 induces interferon in healthy volunteers. Proc. Am. Ass. Cancer Res., 32, 257.
22. WITT PL, RITCH PS, REDING D, MCAULIFFE TL, WESTRICK L, GROSSBERG SE AND BORDEN EC. (1993). Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res., 53, 5176-5180.